ReviewNeurochemical research1999
Oligodendroglial response to the immune cytokine interferon gamma.
Review in Neurochemical research, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- The association of blood biomarkers with cerebral white matter and myelin content in bipolar disorder: a systematic review.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2024Pooled it
- Mechanisms Governing Oligodendrocyte Viability in Multiple Sclerosis and Its Animal Models.Cells · 2024Review
- Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor.Journal of immunology research · 2023Observational
- T cell transgressions: Tales of T cell form and function in diverse disease states.International reviews of immunology · 2022Review
- White matter diffusivity and its correlations to state measures of psychopathology in male refugees with posttraumatic stress disorder.NeuroImage. Clinical · 2022Article
- The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal study.Brain, behavior, & immunity - health · 2021Article
- Prophylactic inhibition of NF-κB expression in microglia leads to attenuation of hypoxic ischemic injury of the immature brain.Journal of neuroinflammation · 2020Article
- Astrocyte-Oligodendrocyte-Microglia Crosstalk in Astrocytopathies.Frontiers in cellular neuroscience · 2020Review
- Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis.Scientific reports · 2019Article
- Effector T Cells in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2018Review
- NF-κB Activation Protects Oligodendrocytes against Inflammation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- The unfolded protein response in multiple sclerosis.Frontiers in neuroscience · 2015Review
- Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases.Critical reviews in immunology · 2015Review
- Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.Cell death and differentiation · 2014Article
- PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases.The American journal of pathology · 2014Article
- Deimination restores inner retinal visual function in murine demyelinating disease.The Journal of clinical investigation · 2013Article
- Article
- Modeling the encephalopathy of prematurity in animals: the important role of translational research.Neurology research international · 2012Article
- The developing oligodendrocyte: key cellular target in brain injury in the premature infant.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2011Review
- TH1 predominance is associated with improved survival in pediatric medulloblastoma patients.Cancer immunology, immunotherapy : CII · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In the human demyelinating disorder multiple sclerosis, and its animal model experimental allergic encephalomyelitis, there is a breakdown of the blood-brain barrier and an infiltration of immune cells into the CNS. Infiltrating T lymphocytes and macrophages are believed to be key mediators of the disease process. Considerable circumstantial and experimental evidence has suggested that the pleiotropic cytokine interferon gamma (IFN-gamma), which is exclusively expressed by T cells and natural killer cells, is a deleterious component of the immune response in these disorders. When experimentally introduced into the CNS IFN-gamma promotes many of the pathological changes that occur in immune-mediated demyelinating disorders. In vitro, this cytokine elicits a number of effects on oligodendrocytes, including cell death. The harmful actions of IFN-gamma on CNS myelin are likely mediated through direct effects on the myelinating cells, as well as through the activation of macrophages and microglia. In this review we summarize relevant studies concerning the action of IFN-gamma in demyelinating disorders and discuss possible mechanisms for the observed effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.